Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin‑bound paclitaxel for human epidermal growth factor receptor 2‑negative breast cancer

  • Authors:
    • Emi Ishigami
    • Masahiro Sakakibara
    • Junta Sakakibara
    • Toshiaki Iwase
    • Shoko Hayama
    • Takahito Masuda
    • Ayako Nakagawa
    • Takeshi Nagashima
    • Takafumi Sangai
    • Hiroshi Fujimoto
    • Masayuki Otsuka
  • View Affiliations

  • Published online on: October 20, 2017     https://doi.org/10.3892/mco.2017.1464
  • Pages:1079-1082
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Neoadjuvant chemotherapy (NAC) with anthracyclines followed by taxane chemotherapy has become the standard treatment for patients with locally advanced, operable breast cancer. Recently, the efficacy of nanoparticle albumin‑bound paclitaxel (nab‑PTX) for metastatic breast cancer was reported. However, there are still few studies of a neoadjuvant regimen including nab‑PTX. Thus, the present phase II study evaluated the efficacy and safety of 5‑fluorouracil, epirubicin and cyclophosphamide (FEC regimen) followed by nab‑PTX as neoadjuvant treatment for operable human epidermal growth factor receptor 2 (HER2)‑negative breast cancer. Women with operable HER2‑negative breast cancer (clinical stage T1a‑4N1‑3) received 4 cycles of FEC (5‑fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2 every 21 days), followed by 4 cycles of nab‑PTX at 260 mg/m2 every 21 days. The patients then underwent mastectomy or breast‑conserving surgery (BCS). The primary endpoint was pathological complete response (pCR) rate. The secondary endpoints included clinical response rate, pathological response rate, BCS rate and safety. A total of 16 patients were evaluated and 3 patients (18%) achieved pCR (1 patient with estrogen receptor‑positive cancer and 2 with estrogen receptor‑negative cancer). The pCR rate was 12 and 25% in patients with estrogen receptor‑positive and ‑negative cancers, respectively. The clinical response rate was 100% (clinical complete and partial response in 6 and 10 patients, respectively). The BCS rate was 31.25%. Three patients experienced grade 3 neutropenia during FEC therapy, and no grade 3/4 events occurred during nab‑PTX therapy. Thus, neoadjuvant therapy with FEC followed by nab‑PTX for operable HER2‑negative breast cancer was found to be a safe and effective option.

Related Articles

Journal Cover

December 2017
Volume 7 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ishigami, E., Sakakibara, M., Sakakibara, J., Iwase, T., Hayama, S., Masuda, T. ... Otsuka, M. (2017). Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin‑bound paclitaxel for human epidermal growth factor receptor 2‑negative breast cancer. Molecular and Clinical Oncology, 7, 1079-1082. https://doi.org/10.3892/mco.2017.1464
MLA
Ishigami, E., Sakakibara, M., Sakakibara, J., Iwase, T., Hayama, S., Masuda, T., Nakagawa, A., Nagashima, T., Sangai, T., Fujimoto, H., Otsuka, M."Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin‑bound paclitaxel for human epidermal growth factor receptor 2‑negative breast cancer". Molecular and Clinical Oncology 7.6 (2017): 1079-1082.
Chicago
Ishigami, E., Sakakibara, M., Sakakibara, J., Iwase, T., Hayama, S., Masuda, T., Nakagawa, A., Nagashima, T., Sangai, T., Fujimoto, H., Otsuka, M."Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin‑bound paclitaxel for human epidermal growth factor receptor 2‑negative breast cancer". Molecular and Clinical Oncology 7, no. 6 (2017): 1079-1082. https://doi.org/10.3892/mco.2017.1464